Company intelligence / Profile preview

LUCA Biologics

Cambridge, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

LUCA Biologics is entering Phase 1b clinical trials for its lead live biotherapeutic targeting recurrent urinary tract infection in women. The product aims to prevent UTI recurrence by restoring the vaginal microbiome. Additional pipeline programs target bacterial vaginosis and preterm birth, all leveraging proprietary microbiome modulation. No clinical results have yet been published as of late 2025.[6][1][3]

Therapeutic areas: Women's HealthInfectious Diseases
Modalities: Live biotherapeutic product therapyMicrobial therapy
Industry: Biotech

Partnerships

Seed Health (foundry incubation and strategic support)[1]Harvard Medical School (clinical partnership)[1]Massachusetts General Hospital (clinical site)[1]

Beyond the preview

Go deeper on LUCA Biologics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LUCA Biologics.

Explore the full profile